Posted On: 12/14/2015 10:27:38 AM
Post# of 72446
" Brilacidin has so many distinct advantages that it could be the go-to drug of choice if FDA approved and marketed."
Just one of the many very positive statements in this press release.
I like how they say that they have plenty of Kevetrin data and that they don't need to stop the Dana-Farber research but can go ahead with the next stage of trials:
"we look forward to initiating an advanced trial in the first half of 2016 under the Orphan Drug designation"
Note that they don't say Phase 2, they say "advanced trial" so it could be a Phase 2/3.
Just one of the many very positive statements in this press release.
I like how they say that they have plenty of Kevetrin data and that they don't need to stop the Dana-Farber research but can go ahead with the next stage of trials:
"we look forward to initiating an advanced trial in the first half of 2016 under the Orphan Drug designation"
Note that they don't say Phase 2, they say "advanced trial" so it could be a Phase 2/3.
(0)
(0)
